Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD. Staudt DE, et al. Clin Proteomics. 2022 Dec 19;19(1):48. doi: 10.1186/s12014-022-09385-7. Clin Proteomics. 2022. PMID: 36536316 Free PMC article.
Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD. Staudt DE, et al. Among authors: skerrett byrne da. Clin Proteomics. 2023 Apr 8;20(1):16. doi: 10.1186/s12014-023-09406-z. Clin Proteomics. 2023. PMID: 37031204 Free PMC article. No abstract available.
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD. Degryse S, et al. Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30. Leukemia. 2018. PMID: 28852199 Free PMC article.
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD. Degryse S, et al. Leukemia. 2018 Dec;32(12):2731. doi: 10.1038/s41375-018-0241-7. Leukemia. 2018. PMID: 30232463 Free PMC article.
Elucidation of the protein composition of mouse seminal vesicle fluid.
Smyth SP, Nixon B, Anderson AL, Murray HC, Martin JH, MacDougall LA, Robertson SA, Skerrett-Byrne DA, Schjenken JE. Smyth SP, et al. Proteomics. 2022 May;22(9):e2100227. doi: 10.1002/pmic.202100227. Epub 2022 Jan 19. Proteomics. 2022. PMID: 35014747
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.
Germon ZP, Sillar JR, Mannan A, Duchatel RJ, Staudt D, Murray HC, Findlay IJ, Jackson ER, McEwen HP, Douglas AM, McLachlan T, Schjenken JE, Skerrett-Byrne DA, Huang H, Melo-Braga MN, Plank MW, Alvaro F, Chamberlain J, De Iuliis G, Aitken RJ, Nixon B, Wei AH, Enjeti AK, Huang Y, Lock RB, Larsen MR, Lee H, Vaghjiani V, Cain JE, de Bock CE, Verrills NM, Dun MD. Germon ZP, et al. Among authors: skerrett byrne da. Sci Signal. 2023 Mar 28;16(778):eabp9586. doi: 10.1126/scisignal.abp9586. Epub 2023 Mar 28. Sci Signal. 2023. PMID: 36976863
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia.
Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Sillar J, Skerrett-Byrne DA, Al Mazi JG, Au GG, de Bock CE, Evans K, Smith ND, Anderson A, Nixon B, Lock RB, Larsen MR, Verrills NM, Dun MD. Murray HC, et al. Leukemia. 2021 Jun;35(6):1782-1787. doi: 10.1038/s41375-020-01050-y. Epub 2020 Oct 16. Leukemia. 2021. PMID: 33067575 Free PMC article. No abstract available.
Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.
Dun MD, Mannan A, Rigby CJ, Butler S, Toop HD, Beck D, Connerty P, Sillar J, Kahl RGS, Duchatel RJ, Germon Z, Faulkner S, Chi M, Skerrett-Byrne D, Murray HC, Flanagan H, Almazi JG, Hondermarck H, Nixon B, De Iuliis G, Chamberlain J, Alvaro F, de Bock CE, Morris JC, Enjeti AK, Verrills NM. Dun MD, et al. Leukemia. 2020 Dec;34(12):3393-3397. doi: 10.1038/s41375-020-0814-0. Epub 2020 Apr 8. Leukemia. 2020. PMID: 32269318 Free PMC article. No abstract available.
42 results